These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
131 related articles for article (PubMed ID: 16251279)
1. Population pharmacokinetics of rifapentine and its primary desacetyl metabolite in South African tuberculosis patients. Langdon G; Wilkins J; McFadyen L; McIlleron H; Smith P; Simonsson US Antimicrob Agents Chemother; 2005 Nov; 49(11):4429-36. PubMed ID: 16251279 [TBL] [Abstract][Full Text] [Related]
2. Consecutive-dose pharmacokinetics of rifapentine in patients diagnosed with pulmonary tuberculosis. Langdon G; Wilkins JJ; Smith PJ; McIlleron H Int J Tuberc Lung Dis; 2004 Jul; 8(7):862-7. PubMed ID: 15260278 [TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of rifapentine at 600, 900, and 1,200 mg during once-weekly tuberculosis therapy. Weiner M; Bock N; Peloquin CA; Burman WJ; Khan A; Vernon A; Zhao Z; Weis S; Sterling TR; Hayden K; Goldberg S; Am J Respir Crit Care Med; 2004 Jun; 169(11):1191-7. PubMed ID: 14962821 [TBL] [Abstract][Full Text] [Related]
4. The early bactericidal activities of rifampin and rifapentine in pulmonary tuberculosis. Sirgel FA; Fourie PB; Donald PR; Padayatchi N; Rustomjee R; Levin J; Roscigno G; Norman J; McIlleron H; Mitchison DA Am J Respir Crit Care Med; 2005 Jul; 172(1):128-35. PubMed ID: 15805182 [TBL] [Abstract][Full Text] [Related]
5. Population pharmacokinetics of rifampicin in Mexican patients with tuberculosis. Milán Segovia RC; Domínguez Ramírez AM; Jung Cook H; Magaña Aquino M; Vigna Pérez M; Brundage RC; Romano Moreno S J Clin Pharm Ther; 2013 Feb; 38(1):56-61. PubMed ID: 23167603 [TBL] [Abstract][Full Text] [Related]
6. Population pharmacokinetics of rifapentine and desacetyl rifapentine in healthy volunteers: nonlinearities in clearance and bioavailability. Savic RM; Lu Y; Bliven-Sizemore E; Weiner M; Nuermberger E; Burman W; Dorman SE; Dooley KE Antimicrob Agents Chemother; 2014 Jun; 58(6):3035-42. PubMed ID: 24614383 [TBL] [Abstract][Full Text] [Related]
8. Population pharmacokinetics of rifampin in pulmonary tuberculosis patients, including a semimechanistic model to describe variable absorption. Wilkins JJ; Savic RM; Karlsson MO; Langdon G; McIlleron H; Pillai G; Smith PJ; Simonsson US Antimicrob Agents Chemother; 2008 Jun; 52(6):2138-48. PubMed ID: 18391026 [TBL] [Abstract][Full Text] [Related]
9. A Population Pharmacokinetic Analysis Shows that Arylacetamide Deacetylase (AADAC) Gene Polymorphism and HIV Infection Affect the Exposure of Rifapentine. Francis J; Zvada SP; Denti P; Hatherill M; Charalambous S; Mungofa S; Dawson R; Dorman S; Gupte N; Wiesner L; Jindani A; Harrison TS; Olagunju A; Egan D; Owen A; McIlleron HM Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30670438 [TBL] [Abstract][Full Text] [Related]
10. Physiologically Based Pharmacokinetic Model of Rifapentine and 25-Desacetyl Rifapentine Disposition in Humans. Zurlinden TJ; Eppers GJ; Reisfeld B Antimicrob Agents Chemother; 2016 Aug; 60(8):4860-8. PubMed ID: 27270284 [TBL] [Abstract][Full Text] [Related]
11. Effects of four different meal types on the population pharmacokinetics of single-dose rifapentine in healthy male volunteers. Zvada SP; Van Der Walt JS; Smith PJ; Fourie PB; Roscigno G; Mitchison D; Simonsson US; McIlleron HM Antimicrob Agents Chemother; 2010 Aug; 54(8):3390-4. PubMed ID: 20516273 [TBL] [Abstract][Full Text] [Related]
12. Disposition and metabolism of 14C-rifapentine in healthy volunteers. Reith K; Keung A; Toren PC; Cheng L; Eller MG; Weir SJ Drug Metab Dispos; 1998 Aug; 26(8):732-8. PubMed ID: 9698286 [TBL] [Abstract][Full Text] [Related]
13. Population pharmacokinetics of doxorubicin: establishment of a NONMEM model for adults and children older than 3 years. Kontny NE; Würthwein G; Joachim B; Boddy AV; Krischke M; Fuhr U; Thompson PA; Jörger M; Schellens JH; Hempel G Cancer Chemother Pharmacol; 2013 Mar; 71(3):749-63. PubMed ID: 23314734 [TBL] [Abstract][Full Text] [Related]
14. The disposition of antituberculous drugs in plasma of elderly patients. II. Isoniazid, rifampicin and pyrazinamide. Walubo A; Chan K; Woo J; Chan HS; Wong CL Methods Find Exp Clin Pharmacol; 1991 Oct; 13(8):551-6. PubMed ID: 1956210 [TBL] [Abstract][Full Text] [Related]
15. Single-dose pharmacokinetics of rifapentine in women. Keung AC; Eller MG; Weir SJ J Pharmacokinet Biopharm; 1998 Feb; 26(1):75-85. PubMed ID: 9773393 [TBL] [Abstract][Full Text] [Related]
16. Protein binding of rifapentine and its 25-desacetyl metabolite in patients with pulmonary tuberculosis. Egelund EF; Weiner M; Singh RP; Prihoda TJ; Gelfond JA; Derendorf H; Mac Kenzie WR; Peloquin CA Antimicrob Agents Chemother; 2014 Aug; 58(8):4904-10. PubMed ID: 24841270 [TBL] [Abstract][Full Text] [Related]
17. Substitution of rifapentine for rifampin during intensive phase treatment of pulmonary tuberculosis: study 29 of the tuberculosis trials consortium. Dorman SE; Goldberg S; Stout JE; Muzanyi G; Johnson JL; Weiner M; Bozeman L; Heilig CM; Feng PJ; Moro R; Narita M; Nahid P; Ray S; Bates E; Haile B; Nuermberger EL; Vernon A; Schluger NW; J Infect Dis; 2012 Oct; 206(7):1030-40. PubMed ID: 22850121 [TBL] [Abstract][Full Text] [Related]